TY - JOUR
T1 - Animal models of chronic and recurrent Pseudomonas aeruginosa lung infection - significance of macrolide treatment
AU - Thomsen, Kim
AU - Kobayashi, Osamu
AU - Kishi, Kenji
AU - Shirai, Ryo
AU - Østrup Jensen, Peter
AU - Heydorn, Arne
AU - Hentzer, Morten
AU - Calum, Henrik
AU - Christophersen, Lars
AU - Høiby, Niels
AU - Moser, Claus
N1 - This article is protected by copyright. All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Animal models of human diseases are invaluable and inevitable elements in identifying and testing novel treatments for serious diseases, including severe infections. Planning and conducting investigator-initiated human trials are generally accepted as being enormously challenging. In contrast, it is often underestimated how much planning, including background and modifying experiments, is needed to establish a relevant infectious disease animal model. However, representative animal infectious models, well designed to test generated hypotheses, are useful to improve our understanding of pathogenesis, virulence factors and host response and to identify novel treatment candidates and therapeutic strategies. Such results can subsequently proceed to clinical testing if suitable. The present review aims at presenting all the pulmonary Pseudomonas aeruginosa infectious models we have knowledge of and the detailed descriptions of established animal models in our laboratory focusing on macrolide therapy are presented.
AB - Animal models of human diseases are invaluable and inevitable elements in identifying and testing novel treatments for serious diseases, including severe infections. Planning and conducting investigator-initiated human trials are generally accepted as being enormously challenging. In contrast, it is often underestimated how much planning, including background and modifying experiments, is needed to establish a relevant infectious disease animal model. However, representative animal infectious models, well designed to test generated hypotheses, are useful to improve our understanding of pathogenesis, virulence factors and host response and to identify novel treatment candidates and therapeutic strategies. Such results can subsequently proceed to clinical testing if suitable. The present review aims at presenting all the pulmonary Pseudomonas aeruginosa infectious models we have knowledge of and the detailed descriptions of established animal models in our laboratory focusing on macrolide therapy are presented.
KW - Animal model
KW - biofilm
KW - chronic lung infection
KW - cystic fibrosis
KW - immunology
KW - macrolide
KW - Humans
KW - Lung
KW - Pseudomonas aeruginosa/physiology
KW - Macrolides/pharmacology
KW - Animals
KW - Cystic Fibrosis/drug therapy
KW - Pseudomonas Infections/drug therapy
KW - Anti-Bacterial Agents/therapeutic use
KW - Disease Models, Animal
UR - http://www.scopus.com/inward/record.url?scp=85110940226&partnerID=8YFLogxK
U2 - 10.1111/apm.13161
DO - 10.1111/apm.13161
M3 - Review
C2 - 34117660
SN - 0903-4641
VL - 130
SP - 458
EP - 476
JO - APMIS - Journal of Pathology, Microbiology and Immunology
JF - APMIS - Journal of Pathology, Microbiology and Immunology
IS - 7
M1 - 13161
ER -